FLX Bio Inc-製薬・医療分野:企業M&A・提携分析

◆英語タイトル:FLX Bio Inc - Pharmaceuticals & Healthcare - Deals and Alliances Profile
◆商品コード:DATA8013416
◆発行会社(調査会社):GlobalData
◆発行日:2017年11月28日
◆ページ数:24
◆レポート言語:英語
◆レポート形式:PDF
◆納品方法:Eメール
◆対象地域:アメリカ
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single UserUSD250 ⇒換算¥37,000見積依頼/購入/質問フォーム
Site License(同一事業所内共有可)USD500 ⇒換算¥74,000見積依頼/購入/質問フォーム
Enterprisewide License(複数事業所内共有可)USD750 ⇒換算¥111,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送しますので、請求書発行日より2ヶ月以内に振込をお願いします。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はGlobalData社の日本における正規販売代理店です。同社発行の企業調査レポートに関するお問い合わせは弊社までお願い致します。
GlobalData社の概要はこちらでご確認いただけます。



【レポートの概要】

Summary
FLX Bio Inc (FLX Bio) focuses on the discovery, development and commercialization of novel immuno-oncology agents. The company’s pipeline product, FLX925 is a drug targeting the FLT3 mutations which is found in patients with acute myeloid leukemia (AML). FLX925 simultaneously targets a second pathway involved in the AML cell growth, known as CDK4/6. FLX Bio is also developing a pipeline of orally-available small-molecule drugs to activate the immune system and eradicate the cancer. The company has advanced into the clinic a dual-inhibitor drug that target FLT3 and CDK4/6 for the treatment of cancer.FLX Bio is headquartered in South San Francisco, California, the US.

FLX Bio Inc – Pharmaceuticals & Healthcare – Deals and Alliances Profile provides you comprehensive data and trend analysis of the company’s Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals – Analysis of the company’s financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year – Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type – Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region – Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector – Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals – Information on the company’s major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description – A brief description of the company’s operations.
- Key Employees – A list of the key executives of the company.
- Important Locations and Subsidiaries – A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors – A list of the key competitors of the company.
- Key Recent Developments – A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company’s financial deals that enable you to understand the company’s expansion/divestiture and fund requirements
- The profile enables you to analyze the company’s financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company’s business segments’ expansion / divestiture strategy
- The profile presents deals from the company’s core business segments’ perspective to help you understand its corporate strategy.

Access elaborate information on the company’s recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company’s key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company’s business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

【レポートの目次】

Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
FLX Bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
FLX Bio Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
FLX Bio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
FLX Bio Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
FLX Bio Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
FLX Bio Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
FLX Bio Raises USD50 Million in Series B Financing 10
Partnerships 12
Cofactor Genomics Enters into Agreement with FLX Bio 12
Licensing Agreements 13
FLX Bio Enters Into Licensing Agreement with Amgen 13
FLX Bio Inc – Key Competitors 14
FLX Bio Inc – Key Employees 15
FLX Bio Inc – Locations And Subsidiaries 16
Head Office 16
Recent Developments 17
Corporate Communications 17
May 31, 2017: FLX Bio Adds Distinguished Immuno-Oncology Experts to its Scientific Advisory Board 17
Dec 12, 2016: FLX Bio appoints new board member 18
Apr 05, 2016: FLX Bio Completes Leadership Team in Immuno-Oncology Drug Discovery 19
Product News 20
12/01/2016: FLX Bio Announces Poster Presentations at the American Society of Hematology Conference on FLX925, a Small Molecule FLT3/CDK4/6 Inhibitor 20
Clinical Trials 21
Sep 21, 2017: FLX Bio Selects Immuno-Oncology Clinical Candidate 21
Mar 31, 2017: FLX Bio to Present Poster at the American Association of Cancer Research Conference on its Lead Immuno-Oncology Program Targeting CCR4 23
Appendix 24
Methodology 24
About GlobalData 24
Contact Us 24
Disclaimer 24

List of Tables
FLX Bio Inc, Pharmaceuticals & Healthcare, Key Facts 2
FLX Bio Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
FLX Bio Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
FLX Bio Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
FLX Bio Inc, Deals By Therapy Area, 2011 to YTD 2017 8
FLX Bio Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
FLX Bio Raises USD50 Million in Series B Financing 10
Cofactor Genomics Enters into Agreement with FLX Bio 12
FLX Bio Enters Into Licensing Agreement with Amgen 13
FLX Bio Inc, Key Competitors 14
FLX Bio Inc, Key Employees 15

★海外企業調査レポート[FLX Bio Inc-製薬・医療分野:企業M&A・提携分析]についてメールでお問い合わせはこちら

■おすすめ企業レポート■
  • Nestle (Malaysia) Bhd:戦略・SWOT・企業財務分析
    Nestle (Malaysia) Bhd - Strategy, SWOT and Corporate Finance Report Summary Nestle (Malaysia) Bhd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerin …
  • HSBC Seguros de Vida Argentina S.A.:企業の戦略・SWOT・財務情報
    HSBC Seguros de Vida Argentina S.A. - Strategy, SWOT and Corporate Finance Report Summary HSBC Seguros de Vida Argentina S.A. - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, …
  • Cheung Kong Infrastructure Holdings Ltd:企業の戦略・SWOT・財務分析
    Cheung Kong Infrastructure Holdings Ltd - Strategy, SWOT and Corporate Finance Report Summary Cheung Kong Infrastructure Holdings Ltd - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT a …
  • Can-Fite BioPharma Ltd (CANF)-製薬・医療分野:企業M&A・提携分析
    Summary Can-Fite BioPharma Ltd (Can-Fite) is a biopharmaceutical company that offers pharmaceutical discovery and clinical development services. The company's pipeline product portfolio includes CF101, CF102 and CF602. It develops its products by utilizing its platform technology based on the Gi pro …
  • Republic National Distributing Company:戦略・SWOT・企業財務分析
    Republic National Distributing Company - Strategy, SWOT and Corporate Finance Report Summary Republic National Distributing Company - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT ana …
  • BelAZ:企業の戦略・SWOT・財務分析
    BelAZ - Strategy, SWOT and Corporate Finance Report Summary BelAZ - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, provid …
  • Advanced Accelerator Applications SA (AAAP):企業の財務・戦略的SWOT分析
    Summary Advanced Accelerator Applications SA (AAA), a Novartis company, is engaged in developing, producing and commercializing diagnostic and therapeutic molecular nuclear medicine products. The company’s lead product candidate comprises Lutathera, NETSPOT, SOMAKIT TOC, Gluscan, Gluscan 500, Barnas …
  • Oncolix Inc (ONCX):製薬・医療:M&Aディール及び事業提携情報
    Summary Oncolix Inc (Oncolix) is a clinical stage biotechnology company. It is developing a targeted therapeutic protein, Prolanta for the treatment of ovarian, breast and other cancers. Prolanta is a recombinant analogue to the human prolactin and acts as an antagonist to the prolactin receptor. On …
  • Sunquest Information Systems Inc:医療機器:M&Aディール及び事業提携情報
    Summary Sunquest Information Systems Inc (Sunquest), a subsidiary of Roper Technologies, is a healthcare information technology (IT) company that provides diagnostic informatics solutions to laboratories and healthcare organizations worldwide. The company offers laboratory informatics such as labora …
  • mBio Diagnostics Inc:医療機器:M&Aディール及び事業提携情報
    Summary MBio Diagnostics Inc (MBio) is a medical device company that offers clinical diagnostics and sample testing solutions. The company offers MBio multiplex analyzer and disposable cartridges. Its MBio Array System is a fluorescence immunoassay system that provides measurement of analytes from a …
  • Metro AG:戦略・SWOT・企業財務分析
    Metro AG - Strategy, SWOT and Corporate Finance Report Summary Metro AG - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions, …
  • AF Gruppen ASA (AFG):企業の財務・戦略的SWOT分析
    AF Gruppen ASA (AFG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Real Matters Inc (REAL):企業の財務・戦略的SWOT分析
    Real Matters Inc (REAL) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses a …
  • Nokia Corp (NOKIA):企業の財務・戦略的SWOT分析
    Nokia Corp (NOKIA) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Bawag Psk
    Bawag Psk - Strategy, SWOT and Corporate Finance Report Summary Bawag Psk - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the company's structure, operation, SWOT analysis, product and service offerings and corporate actions …
  • Braskem SA (BRKM5):企業の財務・戦略的SWOT分析
    Braskem SA (BRKM5) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and th …
  • Tokuyama Corp (4043):企業の財務・戦略的SWOT分析
    Tokuyama Corp (4043) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and …
  • Biogen Inc (BIIB)-医療機器分野:企業M&A・提携分析
    Summary Biogen Inc (Biogen) is a global biotechnology company that manufactures and markets drugs for the treatment of neurodegenerative diseases and rare and autoimmune disorders. Its marketed products include Avonex (interferon beta-1a), Tysabri (natalizumab), Tecfidera (dimethyl fumarate), Zinbry …
  • Medicamen Biotech Ltd (531146):企業の財務・戦略的SWOT分析
    Medicamen Biotech Ltd (531146) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weakn …
  • SES SA (SESG):企業の財務・戦略的SWOT分析
    SES SA (SESG) - Financial and Strategic SWOT Analysis Review provides you an in-depth strategic SWOT analysis of the company’s businesses and operations. The profile has been compiled by GlobalData to bring to you a clear and an unbiased view of the company’s key strengths and weaknesses and the pot …

◆H&Iグローバルリサーチ株式会社のお客様(例)◆